Oral Estradiol and Sleep Architecture: What the Clinical Evidence Shows

Does oral estradiol change sleep architecture?

No sleep-stage study of oral estradiol tablets was identified, so their effect on sleep architecture is unknown. The only sleep-stage data come from one 2000 sleep-EEG study that gave estradiol through the skin [1]. Trials of menopausal hormone therapy that pooled sleep outcomes in a meta-analysis used questionnaires, scales or diaries [2].

What the one sleep-EEG study recorded

A 2000 sleep-EEG study recorded sleep in 11 postmenopausal women with and without estradiol given by skin patch at 50 mcg per day [1]. Estradiol raised REM sleep from 39 plus or minus 5 minutes to 50 plus or minus 4 minutes and cut time awake from 20 plus or minus 6 minutes to 12 plus or minus 5 minutes during the first two sleep cycles, both P<0.05 [1].

Slow-wave sleep changed differently. Estradiol restored the normal fall in slow-wave sleep and delta activity from the first sleep cycle to the second: without estradiol that fall was blunted (-5% plus or minus 14% and -2% plus or minus 5%), and with estradiol it was -56% plus or minus 9% and -20% plus or minus 6% [1]. That is a more typical night-time pattern in 11 women using a patch; the study reported the cycle-to-cycle change, not total deep sleep time.

Self-reported sleep: where the trial data are

A 2017 systematic review and meta-analysis assessed menopausal hormone therapy trials using sleep items from questionnaires, scales or diaries [2]. The review identified 42 trials and pooled seven trials, at moderate to high risk of bias, enrolling 15,468 women [2]. Hormone therapy improved sleep quality in women who had vasomotor symptoms at baseline, standardized mean difference -0.54 (95% CI -0.91 to -0.18). No difference was seen in women without such symptoms [2]. These were hormone therapy trials in general, not trials of oral estradiol tablets specifically, and the outcome was self-reported sleep quality.

What the oral estradiol label covers

Oral estradiol tablets are indicated for moderate to severe vasomotor symptoms of menopause [3]. The label gives a usual initial dose of 1 to 2 mg of estradiol daily for menopausal symptoms, adjusted to symptoms, and says administration should be cyclic (for example 3 weeks on, 1 week off). It says a progestin should also be started in a postmenopausal woman with a uterus [3]. The label still carries its older boxed warning on endometrial cancer and cardiovascular risks; the Women's Health Initiative findings it describes came from oral conjugated estrogens 0.625 mg with medroxyprogesterone 2.5 mg [3].

When the problem is chronic insomnia

The American College of Physicians recommends cognitive behavioral therapy for insomnia (CBT-I) as the initial treatment for chronic insomnia disorder in all adults, adding medication through shared decision-making when CBT-I alone is unsuccessful [4].